Drugs / Plasminogen
Plasminogen
also known as
Human Plasminogen · Plasma trypsinogen · plasminogen, human-tvmh · Profibrinolysin · Prometic Plasminogen (Human) · RYPLAZIM
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06381661 | May 2026 → Jun 2028 expected | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2/32 trials · 1 met primary | ||||||
| Phase 2/3 | NCT02690714 | May 2016 → Dec 2017 | hypoplasminogenemia | Prometic Biotherapeutics, Inc. | Completed | Met primary |
| Phase 2/3 | NCT01554956 | May 2013 → Apr 2014 | ligneous conjunctivitis | Kedrion S.p.A. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04586062 Background | — | ligneous conjunctivitis | Kedrion S.p.A. | Available | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Plasminogen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04586062 ↗ |
| Known as | Human Plasminogen | “Kedrion Human Plasminogen Ophthalmologic Drops” NCT04586062 ↗ |
| Known as | Plasma trypsinogen | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108131 ↗ |
| Known as | plasminogen, human-tvmh | “Plasminogen, human-tvmh (also known as RYPLAZIM®) is the first medicine approved to treat this condition.” PMID 42226455 ↗ Jun 2026 |
| Known as | Profibrinolysin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108131 ↗ |
| Known as | Prometic Plasminogen (Human) | “This is a Phase 2/3 pivotal study to evaluate pharmacokinetics (PK), efficacy, and safety of Prometic Plasminogen (Human) Intravenous Lyophilized Solution, the investigational...” NCT02690714 ↗ |
| Known as | RYPLAZIM | “Plasminogen, human-tvmh (also known as RYPLAZIM®) is the first medicine approved to treat this condition.” PMID 42226455 ↗ Jun 2026 |
| Action | Restore | “It works by replacing plasminogen in the body.” PMID 42226455 ↗ Jun 2026 |
| Modality | Protein / enzyme biologic | “a sterile human plasma-derived plasminogen preparation for topical ocular use” NCT01554956 ↗ |
| Route | Intravenous | “plasminogen, human-tvmh administered intravenously in paediatric and adult subjects with type 1 plasminogen deficiency” PMID 37674358 ↗ Sep 2023 |